Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
1.2500 x 1 1.4100 x 1
Pre-market by (Cboe BZX)
1.3300 +0.0200 (+1.53%) 04/22/25 [NASDAQ]
1.2500 x 1 1.4100 x 1
Pre-market 1.3300 unch (unch) 16:00 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2956
Day High
1.3700
Open 1.3500
Previous Close 1.3100 1.3100
Volume 56,100 56,100
Avg Vol 226,330 226,330
Stochastic %K 61.11% 61.11%
Weighted Alpha -23.67 -23.67
5-Day Change -0.0100 (-0.75%) -0.0100 (-0.75%)
52-Week Range 0.7260 - 3.7800 0.7260 - 3.7800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,766
  • Shares Outstanding, K 63,180
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,050 K
  • EBIT $ -42 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 159.35% ( -17.02%)
  • Historical Volatility 92.44%
  • IV Percentile 54%
  • IV Rank 14.82%
  • IV High 775.99% on 07/01/24
  • IV Low 52.03% on 09/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 274
  • Volume Avg (30-Day) 1,290
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 7,745
  • Open Int (30-Day) 30,641

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +18.75%
on 04/04/25
Period Open: 1.5900
1.8207 -26.95%
on 03/26/25
-0.2600 (-16.35%)
since 03/21/25
3-Month
1.1200 +18.75%
on 04/04/25
Period Open: 1.2100
1.8207 -26.95%
on 03/26/25
+0.1200 (+9.92%)
since 01/22/25
52-Week
0.7260 +83.20%
on 12/20/24
Period Open: 3.0600
3.7800 -64.81%
on 04/29/24
-1.7300 (-56.54%)
since 04/22/24

Most Recent Stories

More News
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

GALT : 1.3300 (+1.53%)
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

GALT : 1.3300 (+1.53%)
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

GALT : 1.3300 (+1.53%)
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

GALT : 1.3300 (+1.53%)
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

GALT : 1.3300 (+1.53%)
TNXP : 14.96 (unch)
CDIO : 0.4100 (+10.81%)
CADL : 4.74 (+5.10%)
RXRX : 5.63 (+4.07%)
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

GALT : 1.3300 (+1.53%)
Galectin Therapeutics Presents Clinical Data on NAVIGATE Trial for Esophageal Varices in MASH Cirrhosis at AASLD 2024

Galectin Therapeutics presents NAVIGATE trial findings on portal hypertension in MASH cirrhosis at AASLD 2024. Results expected December 2024.Quiver AI SummaryGalectin Therapeutics, Inc. has announced...

GALT : 1.3300 (+1.53%)
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

GALT : 1.3300 (+1.53%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

GALT : 1.3300 (+1.53%)
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

GALT : 1.3300 (+1.53%)

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

3rd Resistance Point 1.4425
2nd Resistance Point 1.4063
1st Resistance Point 1.3681
Last Price 1.3300
1st Support Level 1.2937
2nd Support Level 1.2575
3rd Support Level 1.2193

See More

52-Week High 3.7800
Fibonacci 61.8% 2.6134
Fibonacci 50% 2.2530
Fibonacci 38.2% 1.8926
Last Price 1.3300
52-Week Low 0.7260

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro